“炒股”倒亏2亿，双鹭药业2025年大幅亏损！董事长承诺自掏腰包“填坑”

Core Viewpoint - Double-Headed Pharmaceutical (002038.SZ) forecasts a significant decline in net profit for 2025, projecting a loss between 290 million to 200 million yuan, representing a year-on-year decrease of 291.54% to 170.03% [1] Group 1: Financial Performance - The company anticipates a non-recurring net profit loss of between 70 million to 40 million yuan, reflecting a year-on-year decline of 185.02% to 148.58% [1] - In 2024, Double-Headed Pharmaceutical reported an operating revenue of approximately 660 million yuan, a decrease of 35.15% year-on-year, and a net profit attributable to shareholders of -7.407 million yuan, marking the first annual net loss since its listing [2] Group 2: Reasons for Loss - The decline in performance is attributed to two main factors: first, industry policy adjustments and market competition have led to a 10% decrease in sales gross margin for certain products due to falling prices [2] - Second, non-recurring losses have reduced net profit by approximately 200 million yuan, primarily due to losses from financial investments and changes in the fair value of trading financial assets [2] Group 3: Management Response - The company has acknowledged the investment losses in its performance forecast and is actively seeking ways to recover these losses [3] - To protect the interests of minority shareholders, the chairman, Xu Mingbo, has voluntarily committed to cover the unrecoverable portion of the investment losses, initially contributing 50 million yuan to the company within a month [3]